Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors
Research output: Contribution to journal › Journal article › Research › peer-review
PURPOSE: Antihypertensive therapy may improve bevacizumab efficacy in cancer patients. We examined efficacy and toxicity of angiotensin system inhibitors (ASI) and other antihypertensive drugs in bevacizumab treated recurrent glioblastoma patients.
METHODS: We retrospectively combined a national prescription registry with a clinical database with recurrent glioblastoma patients (n = 243).
RESULTS: Patients who initiated ASI after bevacizumab (n = 26) showed a tendency towards improved progression-free survival and overall survival (OS) with hazard rate (HR) reductions (HR = 0.70 and HR = 0.79, respectively). Calcium antagonists during bevacizumab therapy significantly improved OS (HR = 0.57).
CONCLUSIONS: Overall the study supports a potential beneficial effect of antihypertensive treatment on prognosis of bevacizumab treated glioblastoma patients.
| Original language | English |
|---|---|
| Journal | Cancer Investigation |
| Volume | 36 |
| Issue number | 9-10 |
| Pages (from-to) | 512-519 |
| Number of pages | 8 |
| ISSN | 0735-7907 |
| DOIs | |
| Publication status | Published - 2018 |
- Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors/therapeutic use, Bevacizumab/therapeutic use, Brain Neoplasms/drug therapy, Female, Glioblastoma/drug therapy, Humans, Male, Middle Aged, Neoplasm Recurrence, Local/drug therapy, Prognosis, Progression-Free Survival, Retrospective Studies, Young Adult
Research areas
ID: 221751350